Viagra History and Development: From Lab Accident to the World's Most Recognized Pill

The Sandwich Labs: Where Sildenafil Began

Sildenafil's story starts in Sandwich, Kent, England, at Pfizer's UK research facility. In 1989, medicinal chemists Andrew Bell, David Brown, and Nicholas Terrett synthesized compound UK-92,480, a selective inhibitor of phosphodiesterase type 5. Their target was angina pectoris. The hypothesis was straightforward: inhibiting PDE5 would raise cyclic guanosine monophosphate (cGMP) levels in vascular smooth muscle, dilate coronary arteries, and relieve chest pain 1.

The early pharmacology looked promising on paper. PDE5 was known to be abundant in vascular tissue, and cGMP-mediated vasodilation was a well-characterized pathway. Pfizer initiated Phase I clinical trials in 1991 with healthy volunteers in Wales, dosing UK-92,480 orally at escalating levels. The cardiac effects were disappointing. Blood pressure dropped modestly, but the anti-anginal signal was too weak to justify continued development for that indication 2.

Then came the observation that changed everything. Male volunteers in those early trials reported an unexpected side effect: erections. Nurses collecting adverse-event data documented the finding repeatedly. Ian Osterloh, the physician overseeing the trial, recognized the pattern and flagged it to Pfizer's leadership. The decision to redirect the compound toward erectile dysfunction was not immediate. It required internal debate and a corporate willingness to enter a therapeutic area that, at the time, carried significant stigma 2.

How Sildenafil Works: The PDE5 Mechanism

Sildenafil does not directly cause erections. It amplifies the natural erectile response by blocking the enzyme that degrades cGMP in penile corpus cavernosum smooth muscle. Sexual stimulation triggers nitric oxide (NO) release from nerve endings and endothelial cells. NO activates guanylate cyclase, which produces cGMP. This second messenger relaxes smooth muscle, increases arterial inflow, and compresses subtunical venules, trapping blood in the corpora cavernosa 3.

PDE5 normally hydrolyzes cGMP back to inactive 5'-GMP, terminating the signal. Sildenafil competitively inhibits PDE5 at its catalytic site, keeping cGMP levels elevated for a longer duration. The key point: without initial NO release from sexual arousal, sildenafil has no substrate to protect. This is why the drug requires sexual stimulation to work 4.

Sildenafil's selectivity for PDE5 over other phosphodiesterase isoforms is roughly 10-fold over PDE6 (found in retinal photoreceptors, explaining the blue-tinted vision some users report) and greater than 80-fold over PDE1, PDE2, PDE3, and PDE4 1. That selectivity for PDE5 over PDE3, which regulates cardiac contractility, is a major reason sildenafil has a favorable cardiovascular safety profile at therapeutic doses.

The Key Trials That Proved Efficacy

Pfizer launched a formal ED development program in 1993 and conducted over 21 clinical trials enrolling more than 3,000 men. The key publication, Goldstein et al. in the New England Journal of Medicine (1998), reported results from two parallel double-blind, placebo-controlled trials involving 532 men with ED of organic, psychogenic, or mixed etiology 5.

In those trials, men received fixed doses of sildenafil (25 mg, 50 mg, or 100 mg) or placebo taken approximately one hour before sexual activity. The results were striking. At 100 mg, 69% of all sexual attempts resulted in successful intercourse compared to 22% with placebo. Improvements were consistent across subgroups, including men with diabetes, spinal cord injury, and post-radical prostatectomy ED 5.

A separate 24-week dose-response study published by Padma-Nathan et al. (1998) confirmed efficacy across the dose range, with the 50 mg and 100 mg doses producing statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain score. The mean IIEF score increased from 15 at baseline to 22.4 with 50 mg and 25.0 with 100 mg, versus 16.6 for placebo 6.

Most adverse events were mild and dose-dependent: headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%), and abnormal vision (3%) at the 100 mg dose. No serious cardiovascular events occurred at higher rates than placebo in the trial populations 5.

FDA Approval and the 1998 Launch

The FDA approved sildenafil citrate (Viagra) on March 27, 1998, under a priority review. It was the first oral medication ever approved specifically for erectile dysfunction. The speed of uptake was unprecedented in pharmaceutical history. Physicians wrote 40,000 prescriptions in the first two weeks 7.

Before Viagra, men with ED had limited options: penile self-injection with alprostadil (Caverject, approved 1995), intraurethral suppositories (MUSE), vacuum erection devices, or surgical penile implants. Each carried barriers of invasiveness, discomfort, or stigma. An oral tablet taken as needed represented a fundamentally different proposition, and patients responded accordingly.

Bob Dole's public disclosure that he used Viagra after prostate cancer surgery helped normalize the conversation around ED. Within five years of launch, Pfizer's annual Viagra revenue exceeded $1.5 billion globally. The cultural impact was arguably as significant as the clinical one: rates of men seeking ED treatment from their physicians roughly tripled between 1998 and 2003 8.

Safety Debates and the Nitrate Contraindication

Within months of launch, reports of deaths in men taking Viagra prompted headlines and FDA scrutiny. A 1998 analysis identified 130 confirmed deaths among U.S. Viagra users in the first year. Closer examination revealed that most fatalities involved men with severe pre-existing cardiovascular disease, many of whom were co-administered organic nitrates 7.

The pharmacological basis is clear. Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) generate NO, which raises cGMP. Sildenafil blocks cGMP breakdown. Together, the combination can cause precipitous, potentially fatal hypotension. The 1999 ACC/AHA consensus statement formalized the absolute contraindication of PDE5 inhibitors with any form of nitrate therapy 9.

Dr. Arthur Burnett, a urologist at Johns Hopkins who helped establish the NO-mediated mechanism of erection, noted at the time: "Sildenafil is not inherently dangerous to the cardiovascular system. The danger arises from drug-drug interactions that were predictable from the pharmacology" 9. Subsequent long-term safety data confirmed that sildenafil at approved doses does not increase myocardial infarction risk in men without contraindications. A 2002 meta-analysis of 67 placebo-controlled trials found no increase in MI or cardiovascular death rates attributable to sildenafil 10.

Second Life: Pulmonary Arterial Hypertension

Sildenafil's vasodilatory mechanism proved useful beyond ED. PDE5 is highly expressed in pulmonary vascular smooth muscle. In 2005, the FDA approved sildenafil 20 mg three times daily under the brand name Revatio for pulmonary arterial hypertension (PAH) 11.

The SUPER-1 trial (N=278) demonstrated that sildenafil improved six-minute walk distance by 45 meters at the 20 mg TID dose compared to placebo, reduced mean pulmonary arterial pressure, and improved WHO functional class in patients with PAH 11. This represented a meaningful clinical benefit for a disease with a median survival of 2.8 years without treatment at the time.

The PAH indication was a second revenue stream for Pfizer, but it also extended sildenafil's patent protection for that specific use. The Revatio formulation remains on the market today.

Patent Expiration and the Generic Era

Pfizer's core U.S. patent on sildenafil for ED expired in June 2013 (patent extension through pediatric exclusivity delayed generic entry). Teva Pharmaceuticals launched the first generic sildenafil in December 2017 after a settlement with Pfizer. Multiple manufacturers followed, and the price dropped sharply. A 30-tablet supply of generic sildenafil 100 mg fell from over $900 (brand Viagra) to under $30 at many pharmacies by 2020.

Pfizer's peak annual Viagra revenue hit $1.93 billion in 2012, just before the patent cliff. By 2018, Viagra brand sales had dropped to approximately $500 million globally as generics captured market share 12.

The generic transition also enabled new distribution models. Telehealth platforms began offering sildenafil prescriptions through online consultations, dramatically reducing the barrier for men who avoided in-person visits due to embarrassment. This access expansion is a primary reason sildenafil remains the most prescribed PDE5 inhibitor worldwide despite competition from tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra).

Competitors and the PDE5 Inhibitor Class

Viagra's commercial success prompted rapid competitor development. Tadalafil (Cialis) received FDA approval in November 2003. Its 17.5-hour half-life, compared to sildenafil's 3-5 hours, enabled once-daily dosing at 2.5-5 mg for continuous readiness. Vardenafil (Levitra) was approved in August 2003 with similar onset and duration to sildenafil but slightly higher PDE5 selectivity 13.

Avanafil (Stendra), approved in 2012, offered the fastest onset (as early as 15 minutes) with reduced visual and flushing side effects due to greater PDE5 selectivity 14.

Despite these alternatives, sildenafil retains the largest global market share in the PDE5 class. Name recognition matters. "Viagra" remains one of the most searched drug names on the internet, with Google Trends data showing consistent search volume exceeding that of Cialis, Levitra, and Stendra combined.

Ongoing Research and Future Directions

Sildenafil's pharmacology continues to generate clinical investigation beyond ED and PAH. Active areas include Alzheimer's disease research, where a 2021 Cleveland Clinic analysis of insurance claims data for 7.2 million patients found that sildenafil use was associated with a 69% reduced risk of Alzheimer's disease (HR 0.31; 95% CI 0.25-0.38) 15. That association is hypothesis-generating, not causal, and prospective trials are underway.

Other areas of investigation include Raynaud's phenomenon, where sildenafil 50 mg BID reduced attack frequency and severity in a randomized crossover trial 16, and heart failure with preserved ejection fraction (HFpEF), where results have been mixed. The RELAX trial (N=216) showed no improvement in exercise capacity with sildenafil 60 mg TID in HFpEF patients 17.

Sildenafil has also been studied in female sexual dysfunction, altitude sickness, and lymphatic malformations in children. The range of investigation reflects PDE5's distribution across multiple vascular beds. Not every indication has panned out. The negative RELAX trial is a reminder that vascular smooth muscle relaxation does not solve every hemodynamic problem.

The compound that Pfizer nearly abandoned in 1992 because it failed to treat chest pain has generated over $35 billion in lifetime revenue and created an entire therapeutic class. Its development story remains one of the most cited examples of serendipity in pharmaceutical research. The erections that trial volunteers reported were an inconvenient side effect. Recognizing their clinical significance was the real discovery.